Lidocaine enhances antitumor effects of sorafenib and GW5074 in colorectal cancer cells
Targeted therapies have broadened the treatment landscape for colorectal cancer (CRC), highlighting the need for rational combination strategies. Although sorafenib and GW5074 show therapeutic promise and lidocaine may sensitise cancer cells to treatment, the mechanisms underlying these combinations...
Uloženo v:
| Hlavní autoři: | , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Taylor & Francis Group
2026-12-01
|
| Edice: | Journal of Enzyme Inhibition and Medicinal Chemistry |
| Témata: | |
| On-line přístup: | https://www.tandfonline.com/doi/10.1080/14756366.2026.2678755 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|